In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Statin therapy in patients with atherosclerotic cardiovascular disease: is our population under dosed?

Session Poster Session 2

Speaker Muhammad Faisal

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P543

Authors : M Faisal (Karachi,PK), FAWWAD Fawwad (Karachi,PK), SANIYA Saniya (Karachi,PK), MUEED Abdul (Karachi,PK), SAMRA Samra (Karachi,PK), ZUBAIR Zubair (Karachi,PK), SAJID Sajid (Karachi,PK), MUSA Musa (Karachi,PK), FURNAZ Shumaila (Karachi,PK), IMAN Iman (Karachi,PK), ZUBAIR Zubair (Karachi,PK)

Authors:
M Faisal1 , FAWWAD Fawwad1 , SANIYA Saniya1 , MUEED Abdul1 , SAMRA Samra1 , ZUBAIR Zubair1 , SAJID Sajid1 , MUSA Musa1 , FURNAZ Shumaila1 , IMAN Iman1 , ZUBAIR Zubair1 , 1National Institute of Cardiovascular Diseases (NICVD), Adult Cardiology - Karachi - Pakistan ,

Citation:

Introduction: Among patients discharged after a hospitalization for coronary heart disease (CHD) or acute coronary syndrome  (ACS),  high-intensity atorvastatin therapy has been shown in randomized controlled trials to be more effective than either placebo or low/moderate-intensity therapy. Thus, the recent American College of Cardiology (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular risk in adults recommends initiation of high-intensity statin therapy in CHD patients. This is particularly relevant for ACS patients in whom initiation of this therapy is recommended before hospital discharge. The role of prior statins as determinants of post-discharge high-intensity statin use has not been well studied. Therefore this study is designed with aim to determine the frequency and intensity of statin therapy being prescribed to the patients, after a CHD hospitalization.
Objective: To determine the frequency of patients with atherosclerotic cardiovascular disease receiving High Intensity Statin Therapy and types & doses of Statin.

Methods: For this cross-sectional study we enrolled patients above 20 years of age with definitive diagnosis of coronary artery disease presenting at department of our Institute. Demographic characteristics and risk factors such as DM, hypertension, dyslipidemia, and smoking status and information regarding cardiac history, statin therapy, type and dosage level were obtained on a pre designed structural questionnaire.

Results: A total of 238 patients were enrolled in this study, out of which 73.9% (176) were male, mean age of the patients was 56.29 ± 11.94 years. At baseline 41.6% (99) were diabetic, 74.4% (177) were hypertensive, 46.2% (110) were dyslipidemic, 14.7% (35) were current smokers.
Asprin was prescribed to 91.2% (217) of the patients, Clopidogrel to 59.7% (142) patients, Beta Blockers to 78.2% (186) patients, ACE/ ARB to 67.6% (161) patients, and CCB were prescribed to 9.7% (23) patients. Statin was prescribed to 94.5% (225) patients, 29.8% (71) were prescribed with Atorvastatin (10 mg to 50.7%, 20 mg to 47.9%, 40 mg to 1.4%, and 80 mg to 0%) and 66.8% (159) were prescribed with Rosuvastatin (5 mg to 1.9%, 10 mg to 28.3%, 20 mg to 69.2%, and 40 mg to 0.6%). High Intensity Statin Therapy was received by 47.1% (112) patients.
Conclusion: Majority of the patients did not receive High Intensity Statin Therapy after hospitalization for atherosclerotic cardiovascular disease. Whereas, the recent American College of Cardiology(ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommends initiation of high-intensity statin therapy. Reinforcement of guideline in practice is necessary for the better management of our patients.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are